A small retrospective study of 18 patients with recurrent MGM, nine among them with PDGFR-positive tumors, suggested that treatment with the PDGFR inhibitor imatinib mesylate may be a well-tolerated therapeutic option capable of stabilizing disease in a group of patients preselected on the basis of tumor positivity for PDGR [29]. Here, PDGFRB is linked to neoplasm.